Expansion Plans Lonza to Invest 939 Million Dollars for Two New Mammalian Units

Editor: Ahlam Rais

Lonza has plans to make the mega investment in order to build two new mammalian facilities in Visp (CH) and Portsmouth (US). The large-scale facility in Visp (CH) is expected to expand capacity by six 20,000L bioreactors which aims to meet the growing market demand for biologics. The small-scale facility planned in Portsmouth (US) will have a capacity of up to eight 2,000L bioreactors.

Related Company

The new investment reflects Lonza’s commitment to enabling customers to bring drugs to market faster, meet customers’ specific needs and offer end-to-end solutions across multiple modalities and scales.
The new investment reflects Lonza’s commitment to enabling customers to bring drugs to market faster, meet customers’ specific needs and offer end-to-end solutions across multiple modalities and scales.
(Source: Lonza)

Basel/Switzerland – Lonza recently announced significant investments to expand its mammalian drug substance manufacturing facilities in Visp (CH) and Portsmouth (US).

The expansion in Visp (CH) will see the development of a new large-scale mammalian drug substance manufacturing facility to expand capacity with six 20,000L bioreactors to meet increasing market demand in biologics. The new facility will have an area of approximately 27,500 sq m.

The investment will increase large-scale biologics manufacturing capacity to meet customer demand in the contract manufacturing space. The state-of-the-art, high throughput facility includes perfusion capabilities and is designed to support high titer processes and accommodate the next generation of mammalian biologics.

Designed to optimize energy efficiency and water use, the facility is expected to be completed in 2024 and will require an investment of approximately 718 million dollars. The expansion will complement the existing large-scale global network at Lonza sites in Tuas (SG), Portsmouth (US) and Porriño (ES).

In Portsmouth (US), a new next-generation facility supporting late-phase clinical and commercial development and manufacturing will add capacity for up to eight 2,000L single-use bioreactors over an area of 3,000 sq m.

This 221-million-dollar expansion will help meet the increasing market demand for small- to mid-scale mammalian-derived biologics and support the implementation of high titer and high throughput platform processes.

The facility is designed to support Phase 3 clinical and commercial small- to mid-volume products. It will include state-of-the-art technologies in perfusion, purification, and automation.

Combined with Lonza’s industry-leading services in process characterization and process validation, the facility will offer customers an optimized path through BLA to market as well as the flexibility to meet challenges in product forecasting during the initial years of product launch.

The facility is expected to be completed in 2023 and will complement the existing single-use network at Lonza sites in Hayward (US), Slough (UK), Tuas (SG) and Visp (CH).

Following previous investments in mammalian mid-scale capacity, development services and drug product services, the new investment reflects Lonza’s commitment to enabling customers to bring drugs to market faster, meet customers’ specific needs and offer end-to-end solutions across multiple modalities and scales.

Recruitment has already commenced for both of the new facilities. More than 300 new jobs will be created in Visp (CH), while 250 new positions will be recruited in Portsmouth (US), reinforcing Lonza’s commitment to the communities in which it operates.

Pierre-Alain Ruffieux, CEO, Lonza, says, “As we look at the biologics market, we see a combination of growth at pace coupled with continuing high customer demand. In recent months, the Covid-19 pandemic has placed the spotlight on supply chains and the critical role CDMOs play in ensuring an adequate supply of medicines. The expansion of both our large-scale and small-scale manufacturing capacity will ensure Lonza continues to deliver industry-leading contract manufacturing services that will support our customers’ needs in the medium and long term.”

Jean-Christophe Hyvert, President, Biologics and Cell & Gene, Lonza, adds, “At Lonza, we are focused on supporting our customers to achieve efficient, high-throughput production processes and flexible manufacturing solutions. Our customers’ needs range from the manufacture of small- to mid-volume products, such as innovative pharmaceuticals for rare diseases affecting smaller patient populations, to the large-scale commercial production of biologics. These expansions serve to strengthen our position as a critical partner in the development and manufacture of such medicines.”

(ID:47400033)